PEOPLE - Monogram Biosciences makes appointment:
This article was originally published in Clinica
Monogram Biosciences has promoted Gordon Parry to the position of vice-president, R&D, oncology. Dr Parry will have responsibility for Monogram's oncology programmes, including the further development of the San Francisco, California firm's VeraTag technology and the first product based on that platform - the HERMark breast cancer assay. Dr Parry joined Monogram in 2007; before that, he worked for 12 years at Berlex Biosciences where he was the department head of the cancer research department. Previously, he held a variety of research positions in academia, including ten years at the University of California's Lawrence Berkeley Laboratory. He is also an advisory council member for the California Breast Cancer Research Program.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.